105 related articles for article (PubMed ID: 9817384)
1. Intravesical chemotherapy with gamma linolenic acid becomes a realistic prospect in serum-free applications: in vitro cytotoxicity and systemic absorption studies.
Solomon LZ; Jennings AM; Sharpe P; Cooper AJ; Birch BR
J Urol; 1998 Dec; 160(6 Pt 1):2280-3. PubMed ID: 9817384
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
3. Is gamma-linolenic acid an effective intravesical agent for superficial bladder cancer? In vitro cytotoxicity and in vivo tolerance studies.
Solomon LZ; Jennings AM; Hayes MC; Bass PS; Birch BR; Cooper AJ
Urol Res; 1998; 26(1):11-5. PubMed ID: 9537690
[TBL] [Abstract][Full Text] [Related]
4. Intravesical meglumine gamma-linolenic acid in superficial bladder cancer: an efficacy study.
Harris NM; Crook TJ; Dyer JP; Solomon LZ; Bass P; Cooper AJ; Birch BR
Eur Urol; 2002 Jul; 42(1):39-42. PubMed ID: 12121728
[TBL] [Abstract][Full Text] [Related]
5. The effects of meglumine gamma linolenic acid (MeGLA) on an organ culture model of superficial bladder cancer.
Crook TJ; Dyer JP; McCormick RI; Birch BR; Cooper AJ
Urol Res; 2002 Mar; 30(1):59-65. PubMed ID: 11942327
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Solomon LZ; Jennings AM; Foley SJ; Birch BR; Cooper AJ
Br J Urol; 1998 Jul; 82(1):122-6. PubMed ID: 9698674
[TBL] [Abstract][Full Text] [Related]
7. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity.
See WA; Xia Q
J Natl Cancer Inst; 1992 Apr; 84(7):510-5. PubMed ID: 1545441
[TBL] [Abstract][Full Text] [Related]
8. An aqueous formulation of gamma-linolenic acid with anti-proliferative action on human pancreatic cancer cell lines.
Agombar A; Cooper AJ; Johnson CD
Anticancer Drugs; 2004 Feb; 15(2):157-60. PubMed ID: 15075672
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines.
Ilc K; Ferrero JM; Fischel JL; Formento P; Bryce R; Etienne MC; Milano G
Anticancer Drugs; 1999 Apr; 10(4):413-7. PubMed ID: 10378677
[TBL] [Abstract][Full Text] [Related]
10. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
[TBL] [Abstract][Full Text] [Related]
11. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
Long JP; Prout GR; Wong YK; Lin CW
J Urol; 1990 May; 143(5):1053-6. PubMed ID: 2329596
[TBL] [Abstract][Full Text] [Related]
12. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
13. Water as a tumoricidal agent in bladder cancer. In vitro studies in parental and resistant cell lines.
Solomon LZ; Birch BR; Cooper AJ
Eur Urol; 1998 Dec; 34(6):500-4. PubMed ID: 9831792
[TBL] [Abstract][Full Text] [Related]
14. Intravesical chemotherapy with gamma linolenic acid becomes a reality.
Schellhammer PF
J Urol; 1998 Dec; 160(6 Pt 1):1963. PubMed ID: 9817299
[No Abstract] [Full Text] [Related]
15. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.
Kamat AM; DeHaven JI; Lamm DL
Urology; 1999 Jul; 54(1):56-61. PubMed ID: 10414727
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder.
Saxena S; Agrawal U; Agarwal A; Murthy NS; Mohanty NK
BJU Int; 2006 Nov; 98(5):1012-7. PubMed ID: 17034604
[TBL] [Abstract][Full Text] [Related]
17. Regional chemotherapy using continuous intravesical infusion doxorubicin for the treatment of muscle invasive transitional cell bladder carcinoma in a rat model.
See WA; Xia Q; McDermott T; Williams RD
J Urol; 1991 Oct; 146(4):1147-52. PubMed ID: 1895443
[TBL] [Abstract][Full Text] [Related]
18. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
[TBL] [Abstract][Full Text] [Related]
19. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy.
Knuchel R; Hofstadter F; Jenkins WE; Masters JR
Cancer Res; 1989 Mar; 49(6):1397-401. PubMed ID: 2493980
[TBL] [Abstract][Full Text] [Related]
20. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
